155 related articles for article (PubMed ID: 33356483)
1. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
Woldu SL; Ng CK; Loo RK; Slezak JM; Jacobsen SJ; Tan WS; Kelly JD; Lough T; Darling D; van Kessel KEM; de Jong JJ; van Criekinge W; Shariat SF; Hiar A; Brown S; Boorjian SA; Barocas DA; Svatek RS; Lotan Y
J Urol; 2021 May; 205(5):1387-1393. PubMed ID: 33356483
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
Gold SA; Kenigsberg AP; Lotan Y
J Urol; 2022 Jan; 207(1):52-60. PubMed ID: 34428924
[TBL] [Abstract][Full Text] [Related]
3. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
de Jong JJ; Pijpers OM; van Kessel KEM; Boormans JL; Van Criekinge W; Zwarthoff EC; Lotan Y
Eur Urol Oncol; 2023 Apr; 6(2):183-189. PubMed ID: 36089502
[TBL] [Abstract][Full Text] [Related]
4. Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis.
Garg T; Pinheiro LC; Atoria CL; Donat SM; Weissman JS; Herr HW; Elkin EB
J Urol; 2014 Oct; 192(4):1072-7. PubMed ID: 24835058
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of patients with a negative work-up for asymptomatic microhematuria.
Madeb R; Golijanin D; Knopf J; Davis M; Feng C; Fender A; Stephenson L; Messing EM
Urology; 2010 Jan; 75(1):20-5. PubMed ID: 19913883
[TBL] [Abstract][Full Text] [Related]
6. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.
Cha EK; Tirsar LA; Schwentner C; Hennenlotter J; Christos PJ; Stenzl A; Mian C; Martini T; Pycha A; Shariat SF; Schmitz-Dräger BJ
World J Urol; 2012 Dec; 30(6):847-52. PubMed ID: 23124847
[TBL] [Abstract][Full Text] [Related]
7. Variation in the Diagnostic Evaluation among Persons with Hematuria: Influence of Gender, Race and Risk Factors for Bladder Cancer.
Ark JT; Alvarez JR; Koyama T; Bassett JC; Blot WJ; Mumma MT; Resnick MJ; You C; Penson DF; Barocas DA
J Urol; 2017 Nov; 198(5):1033-1038. PubMed ID: 28655530
[TBL] [Abstract][Full Text] [Related]
8. Prospective external validation of a bladder cancer detection model.
Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
[TBL] [Abstract][Full Text] [Related]
9. Progress towards a Nordic standard for the investigation of hematuria: 2019.
Malmström PU; Skaaheim Haug E; Boström PJ; Gudjónsson S; Bjerggaard Jensen J
Scand J Urol; 2019 Feb; 53(1):1-6. PubMed ID: 30636472
[No Abstract] [Full Text] [Related]
10. Predicting bladder cancer risk in patients with hematuria. A single-centre retrospective study.
Jarimba R; Quaresma V; Pedroso Lima J; Eliseu M; Tavares da Silva E; Moreira P; Figueiredo A
Arch Ital Urol Androl; 2023 Mar; 95(1):11026. PubMed ID: 36924379
[TBL] [Abstract][Full Text] [Related]
11. The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.
Khadhouri S; Gallagher KM; MacKenzie KR; Shah TT; Gao C; Moore S; Zimmermann EF; Edison E; Jefferies M; Nambiar A; Mannas MP; Lee T; Marra G; Lillaz B; Gómez Rivas J; Olivier J; Assmus MA; Uçar T; Claps F; Boltri M; Burnhope T; Nkwam N; Tanasescu G; Boxall NE; Downey AP; Lal AA; Antón-Juanilla M; Clarke H; Lau DHW; Gillams K; Crockett M; Nielsen M; Takwoingi Y; Chuchu N; O'Rourke J; MacLennan G; McGrath JS; Kasivisvanathan V;
BJU Int; 2021 Oct; 128(4):440-450. PubMed ID: 33991045
[TBL] [Abstract][Full Text] [Related]
12. The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.
Trojan B; Tang A; Chandrapal J; Filleur S; Nelius T
Ren Fail; 2013; 35(1):72-6. PubMed ID: 23151051
[TBL] [Abstract][Full Text] [Related]
13. The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria.
Gonzalez AN; Lipsky MJ; Li G; Rutman MP; Cooper KL; Weiner DM; Badalato G; Decastro GJ; Wenske S; McKiernan JM; Anderson CB
Urology; 2019 Apr; 126():34-38. PubMed ID: 30677457
[TBL] [Abstract][Full Text] [Related]
14. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample.
Hiatt RA; Ordoñez JD
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):439-43. PubMed ID: 7848421
[TBL] [Abstract][Full Text] [Related]
15. Sex and the Diagnostic Pathway to Bladder Cancer among Veterans: No Evidence of Disparity.
Lynch KE; Viernes B; Khader K; DuVall SL; Schroeck FR
Womens Health Issues; 2020; 30(2):128-135. PubMed ID: 31870696
[TBL] [Abstract][Full Text] [Related]
16. Detection of Upper Tract Urothelial Malignancies by Computed Tomography Urography in Patients Referred for Hematuria at a Large Tertiary Referral Center.
Commander CW; Johnson DC; Raynor MC; Burke LM; Hacker KE; Hoag B; Fielding JR; Semelka RC; Lee ER
Urology; 2017 Apr; 102():31-37. PubMed ID: 28088432
[TBL] [Abstract][Full Text] [Related]
17. Half of visible and half of recurrent visible hematuria cases have underlying pathology: prospective large cohort study with long-term followup.
Mishriki SF; Vint R; Somani BK
J Urol; 2012 May; 187(5):1561-5. PubMed ID: 22425074
[TBL] [Abstract][Full Text] [Related]
18. Microhematuria in Postmenopausal Women: Adherence to Guidelines in a Tertiary Care Setting.
Bradley MS; Willis-Gray MG; Amundsen CL; Siddiqui NY
J Urol; 2016 Apr; 195(4 Pt 1):937-41. PubMed ID: 26523879
[TBL] [Abstract][Full Text] [Related]
19. Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence.
Woldu SL; Souter L; Boorjian SA; Barocas DA; Lotan Y
Urol Oncol; 2021 Nov; 39(11):787.e1-787.e7. PubMed ID: 33858747
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
